Dublin-listed pharma services company Open Orphan has signed a new three year contract with a German pharmaceutical company, which it said will guarantee “significant annual revenue”. Open Orphan, a European-focussed, rare and orphan drug consulting services platform, informed investors of the deal on Monday, but declined to the name the company. “The contract guarantees significant annual revenue with work under the contract to commence this month,” it said. Open Orphan chief executive Cathal Friel said he was building on the partnership with the German company. Open Orphan last month agreed to merge with UK-based Hvivo in a £30 million (€35.7 million) reverse takeover.

Source: The Irish Times January 06, 2020 07:23 UTC